# TMC649128HPC1002 - a Trial inGenotype 1 Hepatitis C Virus (HCV) - Infected Participants to Determine the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of TMC649128, Alone and Combined With Pegylated Interferon + Ribavirin

> **NCT01391117** · PHASE1 · TERMINATED · sponsor: **Tibotec BVBA** · enrollment: 14 (actual)

## Conditions studied

- Hepatitis C Virus

## Interventions

- **DRUG:** placebo.
- **DRUG:** placebo.
- **DRUG:** TMC649128.
- **DRUG:** placebo.
- **DRUG:** placebo
- **DRUG:** TMC649128
- **DRUG:** TMC649128.
- **DRUG:** TMC649128
- **DRUG:** TMC649128.
- **DRUG:** placebo.

## Key facts

- **NCT ID:** NCT01391117
- **Lead sponsor:** Tibotec BVBA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-06
- **Primary completion:** 2011-11
- **Final completion:** 2011-11
- **Target enrollment:** 14 (ACTUAL)
- **Why stopped:** Antiviral activity was considered insufficient to warrant further clinical development of TMC649128.
- **Last updated:** 2012-10-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01391117

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01391117, "TMC649128HPC1002 - a Trial inGenotype 1 Hepatitis C Virus (HCV) - Infected Participants to Determine the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of TMC649128, Alone and Combined With Pegylated Interferon + Ribavirin". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01391117. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*